Abstract 99P
Background
In the era of immunotherapy, whether removal of tumor -draining lymph nodes (TDLNs) should be removed as the traditional surgery way or should be surgical method or preserved preservation remains controversialis still unknown.
Methods
In this study, 42 mismatch repair deficient (dMMR) and 42 mismatch repairs proficient (pMMR) colon cancer patients were enrolled. Imaging data and single-cell RNA sequencing of tumor-draining lymph nodes were also investigated for comprehensive profiling of the microenvironment. The cells of tumor-draining lymph nodes in patients with dMMR colon cancer after neoadjuvant immunotherapy were analyzed to determine their T-cell phenotype.
Results
No significant differences in presurgical clinical characteristics were detected between the dMMR and pMMR groups. However, greater disease-free survival was observed in dMMR patients than in pMMR patients (p =0.02). Approximately 52.4% of patients with dMMR treated with a whole regimen of Pd-1 blockade (dMMR+Pd-1) achieved a pathological complete response (pCR). Eight of the 42 dMMR patients experienced bowel obstruction during treatment. The single-cell transcriptome revealed enrichment of naïve-like CD8+ T cells in the TDLNs of dMMR responders. In addition, we observed that macrophages in dMMR responder TDLNs were polarized toward the M1 phenotype. The altered microenvironment was accompanied by the complete eradication of malignant cells in TDLNs upon Pd-1 blockade treatment.
Conclusions
To maintain a durable response to ICIs, TDLN preservation could be considered a potential reservoir of memory T cells to sustain ICI responses and reduce the risk of relapse and progression in dMMR+Pd-1 blockade colon cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Sun Yat-sen University Cancer Center, Chinese Society of Clinical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract